Related by context. All words. (Click for frequent words.) 73 doxorubicin cyclophosphamide 71 TPV r 71 relapsed MM 70 pegylated liposomal doxorubicin 70 ritonavir boosted 70 tipranavir r 69 dose dexamethasone 69 peginterferon alfa 2b 69 pegylated interferon alfa 2b 69 5-FU/LV 69 abacavir lamivudine 69 mg kg dose 69 fosamprenavir 69 estramustine 69 fluticasone salmeterol 69 hematologic toxicity 69 APTIVUS r 69 morphometric vertebral fractures 68 aPTT 68 LPV r 68 salmeterol fluticasone 68 ibandronate 68 TMC# r 68 mg/m2 dose 68 ritonavir boosted lopinavir 68 genotypic resistance 68 symptomatic VTE 68 CHOP chemotherapy 68 FOLFIRI 68 intermittent dosing 68 ABVD 68 CsA 68 sirolimus eluting stents 68 DOXIL 68 BEACOPP 68 Flu Cy 68 mycophenolate mofetil 68 definite stent thrombosis 68 chemoradiotherapy 68 melphalan prednisone 67 CIMZIA TM certolizumab pegol 67 RAPAFLO R 67 Xelox 67 virological failure 67 lenalidomide dexamethasone 67 adenoma recurrence 67 viral kinetics 67 recurrent glioblastoma multiforme 67 ribavirin RBV 67 salmeterol fluticasone propionate 67 Acute Ischemic Stroke 67 pegylated liposomal doxorubicin PLD 67 steroid dexamethasone 67 darunavir r 67 CCyR 67 neurologic progression 67 ELOXATIN 67 daunorubicin 67 platelet inhibitor 67 pyrazinamide 67 tipranavir 67 Pemetrexed 67 virologic failure 67 fluorouracil 67 CIMZIA TM 67 Elitek 67 Pegasys plus Copegus 67 dose cohort 67 PegIFN RBV 67 clodronate 67 elotuzumab 67 gemcitabine carboplatin 67 plus dexamethasone 67 oral allopurinol 67 evaluating tivozanib 67 ATACAND 67 everolimus eluting stents 67 infusional 5-FU/LV 67 PEG IFN 67 pyridostigmine 67 rFVIIa 67 pegylated interferon alfa 67 placebo dexamethasone 67 boosted protease inhibitor 67 KRAS mutations occur 67 bendamustine 67 oral rivaroxaban 66 oxycodone CR 66 CHAMPION PCI 66 virological response 66 amoxicillin clavulanate 66 XIENCE V PROMUS Stent 66 antithrombotic therapy 66 Velcade bortezomib 66 piperacillin tazobactam 66 dalteparin 66 comparator arm 66 mycophenolate mofetil MMF 66 APTIVUS 66 periprocedural 66 VELCADE melphalan 66 dexamethasone Decadron 66 azacitidine 66 chemoradiation therapy 66 paclitaxel carboplatin 66 irbesartan 66 LEXIVA r 66 ARB telmisartan 66 peginterferon alpha 2a 66 briakinumab 66 trastuzumab Herceptin ® 66 nab paclitaxel 66 CYPHER Stent 66 biologic DMARD 66 prednisone prednisolone 66 concurrent chemoradiation 66 carboplatin paclitaxel 66 CIMZIA ™ 66 certolizumab 66 octreotide LAR 66 Doxil ® 66 β blockers 66 docetaxel chemotherapy 66 teriflunomide 66 standard chemotherapy regimen 66 bolus dose 66 CANCIDAS 66 riociguat 66 cilengitide 66 multicenter randomized placebo controlled 66 dose cytarabine 66 interferon ribavirin 66 Cimzia TM 66 thalidomide Thalomid 66 micafungin 66 ULORIC 66 postoperative chemotherapy 66 #mg/m# [001] 66 FOLPI 66 antiandrogen 66 pegIFN 66 canakinumab 66 MAGE A3 ASCI 66 Durezol 66 reinfarction 66 assessing T DM1 66 paclitaxel Taxol 66 epoetin alpha 66 docetaxel prednisone 66 tenofovir emtricitabine 66 AZT zidovudine Retrovir 66 eptifibatide 66 forodesine 66 Tarceva TM 66 tacrolimus ointment 66 intravenous dosing 66 NSABP B 66 rFSH 66 locoregional recurrence 66 cisplatin gemcitabine 66 randomized Phase IIb 66 neoadjuvant 66 pomalidomide 66 MGd 66 tocilizumab 66 decitabine 66 EBRT 65 complete cytogenetic response 65 anagrelide 65 pertuzumab 65 AST ALT 65 BARACLUDE ® 65 neutrophil counts 65 GOUT 65 FOLFOX4 65 invasive candidiasis 65 efavirenz EFV 65 rosuvastatin #mg 65 HBeAg seroconversion 65 epirubicin cyclophosphamide 65 tirofiban 65 Folfox 65 galiximab 65 virologic response 65 Femara letrozole 65 nadolol 65 Dacogen decitabine 65 fluvastatin 65 androgen suppression 65 desvenlafaxine succinate 65 dosage regimens 65 radiotherapy RT 65 ACTEMRA TM 65 adjuvant cisplatin 65 vidofludimus 65 somatostatin analog 65 liposomal doxorubicin 65 PSMA ADC 65 adalimumab Humira 65 protease inhibitor PI 65 dose melphalan 65 experienced virologic failure 65 fondaparinux 65 4mg/kg 65 RLAI 65 folinic acid 65 zonisamide SR 65 TMP SMX 65 IOP lowering 65 sirolimus eluting stent 65 CYP#D# inhibitor 65 metastatic CRC 65 #mg/day [001] 65 Subgroup analysis 65 dose atorvastatin 65 eosinophilic asthma 65 noninferior 65 PSA nadir 65 SPRYCEL ® 65 vinorelbine 65 multicenter randomized controlled 65 abatacept 65 Kaplan Meier analysis 65 Peg IFN 65 daily subcutaneous injections 65 serum cortisol 65 ertapenem 65 Platinol ® 65 TORISEL 65 EGFR TKI 65 evaluable subjects 65 caspofungin 65 alfa 2a 65 Taxotere ® 65 lenalidomide Revlimid R 65 eplerenone 65 abacavir Ziagen 65 amphotericin B 65 Pegylated Interferon 65 abiraterone acetate 65 cyclophosphamide methotrexate 65 flutamide 65 Toxicities 65 ribavirin therapy 65 trimethoprim sulfamethoxazole 65 nonmetastatic prostate cancer 65 lanthanum carbonate 65 antihypertensive therapy 65 ceftazidime 65 Vidaza azacitidine 65 mapatumumab 65 Cloretazine 65 #mg QD [002] 65 binary restenosis 65 adjuvant tamoxifen 65 platelet reactivity 65 lopinavir r 65 infusional 65 mycophenolic acid 65 lomitapide 65 noninferiority 65 clevidipine 65 docetaxel Taxotere 65 tipranavir ritonavir 65 stavudine d4T 64 IFN alfa 64 receiving highly emetogenic 64 crizotinib PF # 64 paclitaxel Taxol ® 64 rt PA 64 XELOX 64 intravenous cyclophosphamide 64 cinacalcet 64 antiretroviral naïve 64 Aptivus ® 64 taxotere 64 Triapine R 64 placebo controlled clinical 64 PREZISTA r 64 divalproex sodium 64 deferiprone 64 recurrent VTE 64 neoadjuvant chemotherapy 64 Irinotecan 64 AEGR 64 cisplatin vinorelbine 64 cabazitaxel 64 oral Hycamtin 64 moderately emetogenic 64 HBeAg negative patients 64 LV dysfunction 64 Phase Ib clinical 64 comparator PI r 64 % CI #.#-#.# [003] 64 mcg BID 64 tigecycline 64 viral kinetic 64 mitomycin 64 paclitaxel eluting stents 64 idraparinux 64 ritonavir boosted atazanavir 64 Natalizumab 64 serum urate levels 64 thromboembolic events 64 verteporfin 64 relapsed MCL 64 Free Survival PFS 64 Epirubicin 64 bolus injection 64 ACAPODENE 64 d4T stavudine Zerit 64 CALGB # [002] 64 brivaracetam 64 trials RCTs 64 ancrod 64 dose escalation phase 64 relapsing multiple sclerosis 64 atorvastatin #mg 64 ALGRX 64 bupropion SR 64 corticosteroid dexamethasone 64 pegylated interferon alpha 64 Hycamtin ® 64 temsirolimus 64 mitoxantrone 64 sorafenib Nexavar 64 QVA# 64 Non inferiority 64 Phase IIIb clinical 64 alpha 2a 64 atazanavir ritonavir 64 transaminase elevations 64 Pegylated Liposomal Doxorubicin 64 partial remissions 64 idarubicin 64 serum urate 64 interferon alfa 64 DAPT 64 Pegasys ® 64 indinavir 64 NATRECOR ® 64 heavily pretreated 64 rimonabant #mg 64 lenalidomide Revlimid 64 EURIDIS 64 TTF Therapy 64 peginterferon alfa 2a #KD 64 timepoints 64 SVR# 64 SCCHN 64 BENICAR HCT 64 Ceplene/IL-2 64 degarelix 64 peg interferon 64 cisplatin chemotherapy 64 phase IIb trial 64 goserelin 64 ABC/3TC 64 IV bolus 64 mg kg cohorts 64 lumbar spine BMD 64 Combination therapy 64 olmesartan 64 INTELENCE 64 inhibitor RG# 64 lumiliximab 64 acromegalic patients 64 DMARD therapy 64 #mg dose [003] 64 interferon alfa 2b 64 dosing cohort 64 plus gemcitabine 64 rilpivirine 64 AGILECT ® 64 eculizumab therapy 64 unfractionated heparin UFH 64 ORENCIA ® 64 durable remissions 64 debulking surgery 64 PASI scores 64 alkylating agent 64 CLARITY study 64 chlorambucil 64 mcg QD 64 phase IIb study 64 surrogate endpoint 64 trabedersen 64 CLORETAZINE TM VNP#M 64 dose clopidogrel 64 ara C 64 RE LY ® 64 cidofovir 64 sunitinib malate 64 CR CRu 64 APTIVUS R 64 colorectal adenoma 63 gadobutrol 63 Omacetaxine 63 randomized multicenter Phase III 63 cetuximab Erbitux ® 63 antithrombotics 63 Alkeran 63 #mg QD [001] 63 ARCOXIA 63 8mg/kg 63 dose cyclophosphamide 63 irinotecan chemotherapy 63 #mg doses [002] 63 metastatic malignant 63 oral levofloxacin 63 gastrointestinal toxicities 63 imipenem 63 adriamycin 63 lispro 63 maximal dose 63 neutropaenia 63 receiving VICTRELIS 63 Stent thrombosis 63 anthracycline containing 63 sustained virological response 63 tinzaparin 63 corifollitropin alfa 63 Platinol ® cisplatin 63 histologic subtype 63 ritonavir boosted protease inhibitor 63 3TC lamivudine Epivir 63 NNRTI resistance 63 docetaxel Taxotere ® 63 dacarbazine 63 sunitinib 63 microbiological eradication 63 oblimersen 63 active comparator 63 NRTI 63 revascularizations 63 locoregional disease 63 CR nPR 63 #mg dose [001] 63 ipsilateral stroke 63 protease inhibitors PIs 63 pCR 63 Retreatment 63 liposomal formulation 63 pegfilgrastim 63 carboplatin chemotherapy 63 q8h 63 chemotherapy docetaxel 63 NATRECOR R 63 ALT elevations 63 mCRC patients 63 mg BID dose 63 mRCC 63 biochemical relapse 63 Helicobacter pylori eradication 63 severe neutropenia 63 iniparib BSI 63 undetectable HBV DNA 63 androgen deprivation 63 null responder 63 Phase Ib II 63 clomipramine 63 paclitaxel Taxol R 63 nadroparin 63 atazanavir Reyataz 63 iniparib 63 isoproterenol 63 oral ridaforolimus 63 capecitabine Xeloda 63 anemia hemoglobin 63 plus prednisone 63 OHR/AVR# 63 NXL# 63 cobiprostone 63 peginterferon alfa 2a 63 ALA PDT 63 Cypher Stent 63 radiochemotherapy 63 Phase 1a clinical 63 FluCAM arm 63 Fludara 63 5FU 63 leukemia AML 63 pegylated alpha interferon 63 oral anticoagulation 63 resminostat 63 gemcitabine chemotherapy 63 insulin detemir 63 metastatic malignant melanoma 63 FOLFOX6 chemotherapy regimen 63 rilonacept 63 alefacept 63 Neulasta ® 63 multicentre randomized 63 methotrexate monotherapy 63 antithymocyte globulin 63 PegIFN 63 phase IIb clinical 63 sitaxsentan 63 RoACTEMRA 63 mcg doses 63 neratinib 63 levosimendan 63 ZACTIMA 63 elevated troponin 63 LHRH agonists 63 Aloxi injection 63 Noxafil 63 Torisel 63 tolvaptan 63 IFN α 63 mg RDEA# 63 telaprevir dosed 63 Febrile neutropenia 63 candidemia 63 lymphocyte count 63 weekly subcutaneous injections 63 sipuleucel T 63 NOXAFIL 63 CBLC# 63 posaconazole 63 hour bronchodilation 63 mmol kg 63 dose cohorts 63 metastatic castration resistant 63 enalapril 63 paricalcitol 63 TAXOTERE ® 63 prospectively stratified 63 oral diclofenac 63 antiangiogenic therapy 63 chemotherapeutic regimen 63 CYT# QbG# 63 Myelodysplastic Syndrome MDS 63 oral prednisolone 63 proton pump inhibitor PPI 63 Phase 1b trial 63 nonrandomized 63 tumor necrosis 63 CAELYX 63 #Gy 63 Zemplar Capsules 63 oxaliplatin Eloxatin 63 tenofovir FTC 63 Randomized Evaluation 63 temsirolimus Torisel ® 63 unfractionated heparin 63 metastatic GIST 63 potentially hepatotoxic 63 5-fluorouracil/leucovorin 63 DAS# CRP 63 activated partial thromboplastin 63 FOLFOX6 63 HCV RESPOND 2 63 tenecteplase 63 imatinib therapy 63 low dose ritonavir 63 mcg Albuferon 63 composite endpoint 63 achieved ACR# 63 MabCampath 63 tumor lysis syndrome 63 #mg BID [001] 63 pharmacokinetic interactions 63 recurrent GBM 63 LAMICTAL 63 preoperative chemotherapy 63 q#h 63 darunavir ritonavir 63 etanercept Enbrel 63 conventional DMARDs 63 VFEND 62 5 FU leucovorin 62 Amplimexon 62 MS relapses 62 bortezomib Velcade 62 inhaled budesonide 62 eluting stent 62 CIN2 + 62 anti leukemic 62 grade cervical intraepithelial 62 Ziprasidone 62 Imprime PGG 62 Thal Dex 62 peginterferon 62 symptomatic intracranial 62 KRAS mutant tumors 62 saline placebo 62 regorafenib 62 oxymorphone ER 62 achieved statistical significance 62 ascending dose 62 randomized multicenter trial 62 aspirin clopidogrel 62 QTcF 62 angiographic outcomes 62 tapentadol ER 62 ASCT 62 ispinesib administered 62 xanthine oxidase inhibitor 62 intratympanic 62 bortezomib Velcade R 62 gemcitabine cisplatin 62 rapid virological response 62 inhaled treprostinil 62 gemcitabine Gemzar 62 rizatriptan 62 relapsed myeloma 62 investigational antiplatelet 62 plus 5-FU/LV 62 thrombocytopenic 62 OvaRex MAb 62 GnRH agonists 62 macrolide antibiotic 62 remission induction 62 corrected QT interval 62 perioperatively 62 paclitaxel poliglumex 62 recurrent ischemia 62 HSCT 62 intracranial hemorrhage ICH 62 MMX mesalamine 62 antiangiogenic agent 62 liposomal amphotericin B 62 fosbretabulin 62 Zyclara 62 Hepatotoxicity 62 antiangiogenic agents 62 bovine thrombin 62 icatibant 62 azilsartan medoxomil 62 SPIRIVA ® 62 Renal Cell Carcinoma RCC 62 intravenous bisphosphonates 62 remission CR 62 trabectedin 62 nicardipine 62 MCyR 62 dose statin therapy 62 randomized blinded 62 TLK# 62 Mitoxantrone 62 CLL SLL 62 febrile neutropenia 62 lapatinib Tykerb 62 inhaled iloprost 62 ezetimibe simvastatin 62 serum LDL cholesterol 62 PREZISTA ritonavir 62 SCIg 62 ddI 62 lymphopenia 62 oral ibandronate 62 Peginterferon 62 tanespimycin 62 etravirine 62 interferon alfa 2a 62 hemorrhagic complications 62 Taxotere chemotherapy 62 beta blocker therapy 62 immunosuppressive regimen 62 zotarolimus eluting stent 62 DMARD 62 Ramipril 62 prospective multicenter 62 pharmacokinetics PK 62 maximally tolerated dose 62 pamidronate 62 lopinavir r arm 62 invasive ductal 62 Neoadjuvant 62 LHRH agonist 62 sustained virologic response 62 pT3 62 Telintra 62 GnRH agonist 62 anthracycline taxane 62 FUSILEV enhances 62 edifoligide 62 nephrotoxicity 62 MoxDuo TM IR 62 MAS XR 62 intravesical therapy 62 sorafenib Nexavar ® 62 #mg BID [003] 62 Lenalidomide 62 inecalcitol 62 relapsed CLL 62 EDEMA3 62 pegylated IFN 62 RezularTM 62 acute coronary syndromes ACS 62 argatroban 62 hyperphenylalaninemia HPA due 62 cilostazol 62 pT2 62 miconazole Lauriad ® 62 suboptimal adherence 62 intratumoral 62 Temsirolimus 62 invasive aspergillosis 62 haematologic 62 ADVANCE PD 62 Taxol paclitaxel 62 fluoropyrimidine 62 recurrent metastatic 62 plus ribavirin 62 Platinol 62 montelukast 62 sargramostim 62 ACOMPLIA R 62 mitoxantrone plus 62 baminercept 62 dacarbazine chemotherapy 62 STRIDE PD 62 #mg/m# [002] 62 TMC# C# 62 Cytoxan 62 VNP#M 62 antithrombotic 62 Pegylated interferon 62 Erlotinib 62 statin monotherapy 62 vicriviroc 62 virologic 62 simvastatin ezetimibe 62 nucleotide analog 62 peginterferon alfa 62 alteplase 62 Trastuzumab 62 carotid endarterectomy CEA 62 methotrexate therapy 62 subanalysis 62 CD4 + cell 62 Pertuzumab 62 #mg/#mg 62 tamoxifen Nolvadex ® 62 Pred Forte 62 virological suppression 62 antiandrogens 62 NEVO ™ 62 relapsed multiple myeloma 62 FOLFIRI alone 62 pharmacokinetic characteristics 62 virologic failures 62 RAPAFLO 62 ciclosporin 62 Navelbine ® 62 zoledronate 62 #.#/#.# mmHg [001] 62 Decitabine 62 Adjuvant chemotherapy 62 hematopoietic cancers 62 adjuvant radiotherapy 62 Betaferon ® 62 highly emetogenic 62 gemcitabine Gemzar ® 62 AVONEX ® 62 Nebulized 62 ARCALYST ® 62 ziconotide 62 chlorthalidone 62 doxorubicin HCl 62 peg IFN 62 corticosteroid therapy 62 subcutaneous insulin 62 urinary N telopeptide 62 prostate cancer CaP 62 methotrexate MTX 62 thrombolytic agents 62 tecarfarin 62 NCCTG N# 62 recurrent venous thromboembolism 62 follicular lymphoma FL 62 intravitreal injections 62 surgical debulking 62 baseline HbA1c 62 azacytidine 62 dose titration 62 RRMS patients 62 dose ritonavir 62 HbA 1c levels 62 Navelbine 62 bezafibrate 62 Perforomist Inhalation Solution 62 HuMax EGFr 62 viral titers 62 TAXOTERE R 62 paclitaxel cisplatin 62 Acute Coronary Syndromes ACS 62 mg m² 62 Randomized controlled 62 lipid lowering agents 62 dosing interval 62 ZYVOX 62 mg QD 62 myeloablative 62 dose dependently 62 Betaferon R 62 bicifadine 62 Pegasys peginterferon alfa 2a 62 octreotide 62 tesmilifene 62 angiotensin converting enzyme inhibitors 62 colorectal liver metastases 62 paroxetine sertraline 62 nucleotide analogue 62 iodixanol 62 HCV replicon 62 Copegus ribavirin 61 FROVA 61 intravenously administered 61 #beta estradiol 61 ximelagatran 61 BRAF inhibitor 61 aprepitant 61 Dose escalation 61 DOXIL ® 61 VADT 61 pharmacokinetic PK study 61 budesonide pMDI 61 Nexavar sorafenib 61 Targretin capsules 61 DEB# 61 pimecrolimus cream 61 MACCE 61 AGILECT R 61 concomitant medications 61 EVIZON 61 mCi kg 61 adjunctive placebo 61 external genital lesions 61 refractory AML 61 Fulvestrant 61 recurrent glioblastoma 61 cediranib 61 completely resected 61 Nilotinib 61 statistically significant p = 61 virologic responses 61 glatiramer acetate 61 HBeAg negative 61 antiplatelet agent 61 liver metastasis 61 REYATAZ ritonavir 61 FOLFOX 61 Darusentan 61 intravesical 61 ZOLINZA 61 TAXUS Stent 61 ALVESCO 61 beclomethasone dipropionate 61 palifosfamide 61 metastatic renal cell carcinoma 61 otamixaban 61 azathioprine 61 GW# [003] 61 gliclazide 61 oral FTY# 61 biochemical recurrence 61 thiazide diuretic 61 vinca alkaloid 61 INTEGRILIN ® 61 microgram kg 61 Bioequivalence 61 Pharmacokinetics PK 61 plus COPEGUS 61 atrioventricular block 61 oral vancomycin 61 tinidazole 61 infliximab monotherapy 61 palonosetron 61 FTC TDF 61 double blinded randomized 61 unboosted 61 dipyridamole plus 61 timolol 61 Darunavir 61 TNF antagonist 61 metastatic hormone refractory 61 formoterol fumarate 61 adecatumumab 61 immunocompetent patients 61 SSRI SNRI 61 serum antibody 61 RSD# oral 61 delafloxacin 61 interferon gamma 1b 61 achieving PASI 61 Apidra ® 61 plus methotrexate 61 vincristine doxorubicin 61 #mg dose [002] 61 relapsed refractory multiple myeloma 61 doripenem 61 reteplase 61 FDG-PET/CT 61 PSADT 61 IFN beta 61 PEGINTRON TM 61 Halaven 61 neoadjuvant treatment 61 antiarrhythmic drug 61 antiviral efficacy 61 serum HBV DNA 61 Virologic 61 postmenopausal osteoporotic women 61 therapeutic regimens 61 Phase Ib study 61 budesonide foam 61 polymyxin B 61 androgen blockade 61 maximal doses 61 Lamotrigine 61 PhG alpha 1 61 low dose cytarabine 61 progression TTP 61 aldosterone antagonists 61 ELACYT 61 VIAject ™ 61 heavily pretreated patients 61 BR.# 61 ER CHOP 61 beta interferons 61 Aggrenox R 61 uric acid lowering 61 treatment naive genotype 61 intradermal injection 61 Randomised 61 interferon α 61 voriconazole 61 pimecrolimus 61 TAXUS Express Stent 61 ganetespib 61 ACE inhibitor ramipril 61 acyclovir Lauriad R 61 topotecan 61 intravenous bolus 61 TDF FTC 61 basiliximab 61 IIIa inhibitor 61 clinically meaningful improvement 61 virologic breakthrough 61 Quinamed 61 % CI #.#-#.# [007] 61 BCIRG 61 CIN3 61 endometrial carcinoma 61 mL/min/#.# m 2 61 YERVOY 61 MYLOTARG 61 multicenter Phase II 61 haematological toxicity 61 HGS# 61 oral prednisone 61 ® lenalidomide 61 Kivexa 61 pharmacologically active isomer 61 enzastaurin 61 XIENCE V demonstrated 61 rituximab Rituxan 61 relapsed AML 61 HoFH 61 cyclophosphamide doxorubicin vincristine 61 subcutaneously administered 61 blinded randomized placebo controlled 61 clopidogrel Plavix 61 NSTE ACS 61 corticosteroid dose 61 QTc prolongation 61 non squamous NSCLC 61 posttreatment 61 TO AVOID PREGNANCY WHILE 61 thrombus aspiration 61 antimetabolite 61 neoadjuvant therapy 61 ChronVac C R 61 #mg/kg [002] 61 etoposide 61 REYATAZ R 61 homocysteine concentrations 61 ethambutol 61 dose Iluvien 61 custirsen 61 Protelos 61 VIR# 61 monotherapy 61 EXJADE 61 FDG PET imaging 61 antihypertensive agents 61 pioglitazone HCl 61 apremilast 61 μg kg 61 moderate renal impairment 61 Androxal TM 61 ACE Inhibitor 61 HGPIN 61 fluticasone furoate 61 recurrent malignant glioma 61 glycosylated hemoglobin levels